Your session is about to expire
← Back to Search
Semaglutide for Nicotine Addiction
Study Summary
This trial will examine whether a GLP-1 receptor agonist can reduce nicotine intake and reinstatement in smokers.
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2020 Phase 4 trial • 104 Patients • NCT04189848Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- Group 1: Sham/Placebo
- Group 2: Semaglutide
Frequently Asked Questions
Are there any patients who have not yet been enrolled in this research project?
"Yes, this trial is recruiting patients according to the information found on clinicaltrials.gov. The listing was first put up on October 7th, 2020 and was last updated two weeks ago on October 21st, 2020."
How many people are currently participating in this research?
"That is correct, the clinical trial mentioned is presently looking for 48 participants from 1 location, as per the information found on clinicaltrials.gov. The trial was initially posted on 10/7/2022 and was most recently edited on 10/21/2022."
Did the FDA greenlight Semaglutide for public consumption?
"Semaglutide received a 2 for safety because, although Phase 2 trials have not yet assessed efficacy, there is some data supporting safety."
Do I meet the requirements to join this test group?
"This research team is looking for 48 individuals that have nicotine dependence and are aged 21-65."
Are people of all ages welcome in this trial, or are there restrictions?
"The age limit for this particular trial is 21-65, however there are 5 other trials open to people who are under 18 and 81 trials available for those who are over 65."
Who else is applying?
What state do they live in?
What site did they apply to?
What portion of applicants met pre-screening criteria?
How many prior treatments have patients received?
Why did patients apply to this trial?
What questions have other patients asked about this trial?
How responsive is this trial?
Typically responds via
Most responsive sites:
- University of North Carolina: < 48 hours
Average response time
- < 2 Days
Share this study with friends
Copy Link
Messenger